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Abstract
Introduction: Extended-spectrum β-lactamases (ESBLs)-producing 
Enterobacteriaceae are a clinical threat that may cause nosocomial 
as well as community-acquired infections. E.coli and Klebsiella pneu-
moniae are among the most common Gram-negative bacilli caus-
ing urinary tract infections. This study investigated certain molecular 
characteristics of phenotypically proved ESBL-producing E. coli and K. 
pneumoniae.
Materials and Methods: This study includes a total of 64 community 
and hospital-acquired Enterobacteriaceae suspected to produce ESBLs 
using routine antimicrobial susceptibility test. Identification of species 
of Enterobacteriaceae was done by the API 20E identification system. 
ESBL production was detected by double disk synergy test (DDST) 
followed by detection of the encoding genes by PCR using primers 
for bla-TEM, bla-CTX-M1, bla-CTX-M2, bla-SHV and bla-PER genes.
Results: The identity of confirmed isolates was 40 E.coli and 24 Kleb-
siella pneumonie. Out of these, 49 isolates were positive for ESBL-
production by DDST. Fifty seven isolates were proved to produce ESBLs 
using PCR. The bla-TEM, bla-CTX-M1 and bla-PER were the most 
prevalent ESBL genes (45.3%, 45.3% and 34.375%; respectively). 
Conclusion: The double disk synergy test showed sensitivity of 82.5% 
compared to PCR. The study showed high prevalence of ESBLs in E. 
coli and K. pneumonie isolates from urine specimens with bla-TEM, 
bla-CTX-M1 and bla-PER as the predominant detected genes.
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Introduction
 
Infections due to extended-spectrum beta-lacta-
mase-producing Enterobacteriaceae are associated 
with impaired outcome, delay in administration of 
adequate antimicrobial chemotherapy and can be 
associated with serious complication [1]. The most 
evolving mechanism of ESBL production among En-
terobacteriaceae is the selective pressure imposed 
by inappropriate use of third generation cephalo-
sporins, most often encountered in ICU settings [2]. 
Patients at high risk for developing colonization or 
infection with ESBL-producing organisms are often 
seriously ill patients with prolonged hospital stay 
and often are exposed to invasive medical devices 
(urinary catheters, endotracheal tubes, central ve-
nous lines) for a prolonged duration [3]. ESBLs are 
ß-lactamases capable of conferring bacterial resist-
ance to the penicillin and all generation cephalo-
sporins as well as aztreonam; but not the cepha-
mycins such as cefoxitin and cefotetan or carbapen-
ems, although they can hydrolysis these antibiotics. 
However, ESBLs are inhibited by ß-lactamase inhibi-
tors such as clavulanic acid, tazobactam and sulbac-
tam [4]. Most of the genes encoding class A ESBLs 
are plasmid-borne which may facilitate the intra- or 
inter-species exchange of the resistance genes, re-
sulting in the acquisition of new resistance pheno-
types [5-7]. When a significant proportion of Gram-
negative isolates emerged as ESBL-producers in any 
patient, empirical therapy may change towards the 
use of imipenem, quinolones, or beta-lactamase in-
hibitor combinations [8]. Endemic transmission of 
ESBL-producers can be controlled by appropriate 
infection control measures and prudent antibiotic 
management interventions [4]. Reliable detection of 
ESBL-producers by clinical microbiology laboratory 
is essential to provide appropriate therapy and to 
control nosocomial outbreaks [9, 10].
The aim of the present study was to detect com-
mon ESBL-producing Enterobacteriaceae ( E.coli and 
K. pneumoniae ) by Double Disk synergy test (DDST) 
and to compare it by molecular characterization of 
common genes encoding ESBLs using PCR.
Material and Methods
Bacterial isolates. This study was conducted on 
64 non-duplicate community and hospital-acquired 
isolates of Enterobacteriaceae during the last 3-year. 
The isolates were selected first by routine disk dif-
fusion method due to their reduced susceptibility to 
any of the 3rd generation cephalosporins (e.g. ce-
fotaxime, ceftazidime, cefoxitin, ceftriaxone instead 
cefoxitin) and/or aztreonam. All isolates were ob-
tained from urine samples cultured on MacConkey’s 
agar (Oxoid Hampshire, England) and were incubat-
ed aerobically at 37°C 24-48 hours. Conventional 
microbiological standard tests (Gram stain, glucose 
fermentation test and oxidase test) were used. All 
isolates found to be Gram-negative, glucose fer-
menter, glucose and oxidase negative were consid-
ered preliminary to be Enterobacteriaceae [10]. 
Identification of bacterial isolates. Identifica-
tion species of Enterobacteriaceae after culture on 
MacConkey’s agar was done by the API 20E identifi-
cation system (bioMérieux, France) in accordance to 
manufacture recommendation. This study included 
40 E. coli and 24 K. pneumoniae isolates.
Primary Screening for ESBLs. Antimicrobial 
susceptibility was determined by Kirby-Bauer’s disk 
diffusion method on Mueller-Hinton agar accord-
ing to the specification of Clinical and Laboratory 
Standards Institute (CLSI) [11]. All Isolates showing 
reduced susceptibility to one or more of the used 
antibiotics ceftazidime (CAZ) (30 µg), cefotaxime 
(CTX) (30 µg), cefpodoxine (CPD) (10 µg) and az-
treonam (ATM) (30 µg) (Biorad, France) are consid-
ered to be potential ESBL- producers and additional 
phenotypic tests are mandatory to confirm ESBL-
production [11, 12]. 
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Phenotypic detection of ESBLs using the 
Double-disk Synergy-test (DDST)
 Mueller-Hinton agar was inoculated with a sus-
pension of the test strain equivalent to 0.5 Mc-
Farland turbidity-standard. DDST was employed 
by placing cefotaxime (30µg), ceftazidime (30µg), 
cefpodoxime (10µg) and aztreonam (30µg) disks 
(Biorad) around amoxicillin/clavulanic acid disk (20 
μg and 10 μg, respectively) at a distance of 30 mm 
center to center. Following an overnight aerobic in-
cubation at 37°C, clearly visible extension of the 
edge of the inhibition zone of any disk towards the 
amoxicillin/clavulanic acid disk was interpreted as 
phenotypic evidence of ESBL-production [11]. 
Genotypic detection of ESBL genes using PCR 
DNA Extraction of bacterial isolates was done 
using Biospin Bacteria Genomic DNA Extraction Kit 
(BioFlux corporation, Tokyo, Japan). Amplification of 
the following resistance encoding genes; blaTEM, 
blaSHV, blaCTX-M1, blaCTX-M2 and blaPER; was 
performed by extracted DNA of each isolate. Five 
sets of primers specific for each resistance gene 
were designed according to the GenBank database 
and their sequences are listed in Table 1 [13-17]. 
Dream TaqTM Green PCR Master Mix (2X) 200 reac-
tions of 50μl (Thermo- Fermentas, California, USA) 
(Dream TaqTM DNA polymerase, optimized Dream 
TaqT MGreen buffer, 4mμ MgCl2, density reagents, 
2 dyes for monitoring electrophoresis process and 
0.4 mμ from each of dATPs, dCTP, dGTP and dTTP). 
Amplification was achieved using the PCR Biometra 
T-Personal thermal cycler (48 wells, Ver 09/10, Ger-
many). Five μl of the extracted DNA was added to 
25μl of PCR master mix, 1μ of each primer, 10μl 
nuclease free water to reach a final volume of 50μl. 
The amplification process was done according to 
the manufacturer’s instructions as follows: an initial 
denaturation cycle at 95oC for 5 minutes; 35 cycles 
consisted of denaturation at 95oC for 30 seconds, 
annealing at temperature ranged from 56 to 82oC 
for 1 minute and primer extension at 72oC for 2 
minutes; with an additional 10 minutes incubation 
at 72°C after completion of the last cycle. At the 
end of amplification process, the maintenance tem-
perature was 4°C. 
Detection of the amplified DNA products
The amplified DNA products sizes were detected 
using 2% agarose gel elec trophoresis and molecular 
size marker (100-1000 base pair), and the bands 
were visualized by UV transilluminator (Biometra, TI). 
Product sizes of the amplified genes are shown in 
Table 1.
Table 1. Specific primer sequences used in the detection of ESBLs genes and the amplified product sizes.
Genes Primer sequences Product size Ref.
TEM
5’-ATGAGTATTCAACATTTCCG-3´
5´-CCAATGCTTAATCAGTGAGG-3´
 858 bp [13]
SHV
5´-CTTTACTCGCTTTATCG-3´
5´-TCCCGCAGATAAATCACCA-3´
827 bp [14]
CTX-M1
5´-AGTTCACGCTGATGGCGACG-3´
5´-AACCCAGGAAGCAGGCAGTCC-3´
676 bp [15]
CTX-M2
5´CGGAATTCATGATGACTCAGAGCATG3´
5´GCTCTAGATTATTGCATCAGAAACCG3´
896 bp [16]
PER
5´-AATTTGGGCTTAGGGCAGAA-3´
5´-ATGAATGTCATTATAAAAGC-3´
925 bp [17]
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This study was carried out in the department of 
Medical Microbiology and Immunology and the de-
partment of Medical Biochemistry and Molecular 
Biology, Faculty of Medicine, Cairo University during 
the period from March, 2013 to August 2015. A 
permission was obtained from the Institutional Ethi-
cal Review Board (IERB) of Cairo University, Egypt.
Statistical Analysis 
Data were statistically described in terms of 
frequencies (number of isolates) and percentag-
es. Comparisons were done using McNemar test. 
Agreement between the different diagnostic tests 
was tested using kappa statistic. P values less than 
0.05 was considered statistically significant. All sta-
tistical calculations were done using computer pro-
grams SPSS (Statistical Package for the Social Sci-
ence; SPSS Inc., Chicago, IL, USA) version 15 for 
Microsoft Windows.
Results
Identification of the Enterobacteriaceae
The 64 ESBLs-producing Enterobacteriaceae in-
cluded in this study which were isolated from urine 
samples were identified to be 40 E. coli (62.5%) and 
24 K. pneumoniae (37.5%). 
Primary Screening for ESBLs
All of the 40 E. coli and the 24 K. pneumoniae 
isolates were resistant to one or more of the tested 
β-lactam antibiotics (CTX, CAZ, CPD, ATM) as il-
lustrated in Table 2.
Phenotypic detection of ESBLs using the double-
disk Synergy-test (DDST) showed that 31(77.5%) of 
E. coli isolates were positive for ESBL by DDST, and 
18 (75%) of K. pneumoniae isolates were positive 
for ESBL. 
Number and percentage of E. coli and K. pneu-
moniae isolates showing positive synergism in rela-
tion to the tested antibiotics are demonstrated in 
Table 3.
Table 3: Number and percentage of E. coli & K. 
pneumoniae isolates showing positive synergism in 
relation to the used antibiotics
Antibiotics
Negative synergism 
No. (%)
Positive 
synergism No. (%)
CTX 13 (20) 51 (80)
CAZ 7 (11) 57 (89)
CPD 33 (52) 31 (48)
ATM 8 (12.5) 56 (87.5)
Table 2. Antibiotic susceptibility testing used for screening of E. coli and K. pneumoniae 
 Antibiotic
Number ( %) of resistance
Disk content
E. coli
N = 40
K. pneumoniae
N = 24
CTX 30µg 28 (70) 18 (75)
CAZ 30µg 19 (47.5) 20 (83.3)
CPD 10µg 35 (87.5) 15 (62.5)
ATM 30µg 11 (27.5) 10 (41.67)
CTX = Cefotaxime, CAZ = Ceftazidime, CPD = Cefpodoxime, ATM = Aztreonam.
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Fifty seven isolates (89.1%) out of the 64 isolates 
were positive for ESBL and only 7 isolates (10.1%) 
yielded negative results. Distribution of the resist-
ance encoding genes among E. coli and K. pneu-
moniae is illustrated in Table 4. 
Discussion
The emergence and spread of multidrug resist-
ance among E. coli and K. pneumoniae particularly 
ESBL-producers complicate therapy and limit treat-
ment options. The influx of these bacteria into hos-
pitals has major implications for infection-control 
and empirical treatment strategies [7, 18, 19]. The 
increased incidence of community-acquired ESBLs 
poses an additional challenge for clinical microbio-
logical laboratories to be detected among multid-
rug-resistant pathogens [20]. 
In the present study, we found frequently ESBL-
producers E. coli (62.5%) and K. pneumonia (37.5%) 
in urine samples of patients.This finding is in agree-
ment with Poupet et al. 2008, who reported that 
E. coli and Klebsiella species were the most fre-
quently recovered isolates among ESBL-positive En-
terobacteriaceae in clinical samples [21]. A study 
performed by Kateregga et al. 2015, also reported 
that E. coli was the most common ESBL-producers 
(53.9 %) isolated from urine samples, followed by 
K. pneumoniae (28.7 %) [22]. The predominance of 
E. coli isolates from urine samples was in concord-
ance with a study done in Lebanon by Daoud et al., 
2015, which has compared between two periods of 
2005 and 2012, and stated that ESBL-producing E. 
coli was isolated in 60.53% and 73.98%, while K. 
pneumoniae was isolated in 5.32% and 8.33 %, 
respectively [23].
This study found that all 64 isolates were re-
sistant to one or more of the tested antibiotics as 
shown in Table 3. 
A study conducted by Maina et al 2011, has 
reported that β-lactamase producing Enterobac-
teriacea in the community accounted for 65.4 % 
resistance to CTX and 21.2 % resistance to CAZ 
[20]. Another study done by Katterega et al. 2015 
showed a higher resistance to CAZ (73%) compared 
to CTX (57.5%) in ESBL-producing Enterobacte-
riaceae collected from patients in various wards of 
Mulago Hospital, Uganda [22]. The different rates 
seen in these studies could be due to regional dif-
ferences and the type of samples collected [11, 12]. 
In addition, phenotypic methods for detection of 
ESBLs are not constantly accurate. In contrast, the 
genotypic method using specific PCR amplification 
of resistance genes seems to have 100% specificity 
and sensitivity [24]. The distribution of ESBL among 
E. coli and K. pneumoniae isolates by DDST and PCR 
Table 4: Distribution of the resistance encoding genes among E. coli and K. pneumoniae
Presence of
ESBL
Gene
Number ( %) of positive isolates
E. coli
N = 40
K. pneumoniae
N = 24
Total N= 64
bla-CTX-M1 18 (45) 11 (45.8) 29 (45.3)
bla-CTX-M2 3 (7.5) 3 (12.5) 6 (9.4)
bla-SHV 4 (10) 10 (41.7) 14 (21.9)
bla-TEM 22 (55) 7 (29.2) 29 (45.3)
bla-PER 13 (32.5) 9 (37.5) 22 (34.4)
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is shown in Table 5. DDST showed a sensitivity of 
82.5% for ESBL detection in relation to PCR. This 
finding was lower than a study done by Nandagopal 
et al. 2015 who reported 96.9% sensitivity of DDST 
to detect ESBL-producing Enterobacteriaceae [25]. 
All Clinical isolates of Enterobacteriaceae found to 
produce ESBLs should be assumed to be resistant 
to all extended spectrum cephalosporins irrespec-
tive the results in vitro susceptibility testing [12]. 
In our study the percentage of the detected ES-
BLs genes by PCR were 45.3% for TEM, 45.3% for 
CTX-M1, 34.4% for PER, 21.9% for SHV and 9.4% 
for CTX-M2. A recent study of Daoud et al. 2015 
in Lebanon, has reported that the detected ESBLs 
genes from E. coli and K. pneumoniae were SHV 
(30.69%), TEM (68.19%) and CTX-M (100%) [23]. 
While Nandagopal et al. 2015 in India, has reported 
less incidence rates of genes of CTX-M2 (28.5%) , 
TEM (23.4%) and 4.7% for SHV [25]. In an older 
study conducted by Welsh et al. 2007 in India hos-
pital, CTX-M was also the most common genotype 
isolated [26]. Similar results have been documented 
in Europe, Latin America and other countries [27]. A 
study conducted by Al-Algamy et al. 2015 in Saudi 
Arabia, has found that ESBL-producing K. pneumo-
niae using PCR for detection of SHV, TEM, CTX-M 
β-lactamase genes have prevalence rates of 97.3%, 
84.1%, and 34.1%, respectively [28]. It is well 
documented that the CTX-M genotypes which are 
chromosomally encoded has been recently sharply 
increased in Escherichia coli and K. pneumoniae in 
different geographical regions of the world includ-
ing Middle East Arab countries [28,29].
Conclusion
Routine detection of ESBL-producing E. coli and 
K. pneumoniae in the laboratories plays a critical 
role for their control. Molecular identification of 
ESBL encoding genes is essential for a reliable inves-
tigation of their antimicrobial resistance. The need 
for new treatment strategies and prudent use of an-
timicrobials at each segment of healthcare services, 
continuous monitoring, effective infection control 
measures are essential to minimize the emergence 
and spread of multidrug resistant pathogens.
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